ClinicalTrials.gg
CompletedNCT06645795RAGTNEUDEVUpdated Oct 16, 2026

Robot Asissted Training on Neurodevelopmental Alterations

An interventional study of Robot assisted gait training plus conventional physical therapy and Conventional pjysical therapy in Neurodevelopmental Disorders and Cerebral Palsy, sponsored by University of Valencia. Completed at 1 site in Spain. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Valencia · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
1 Year to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Neurodevelopmental Disorders with a site in Spain — 7 open to participants now, 11 under way, 5 of them phase 3. Neurodevelopmental Disorders · Spain.

Enrollment
16th of 16
9 · median 60
Started
2024
with 4 others
No phase
9 of 20
3 open now
Registered
9th of 20
by date

Among the 20 studies in Neurodevelopmental Disorders with a site in Spain, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 with no phase, and was the 9th registered.

Neurodevelopmental Disorders

355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

7 of the 20 studies in Neurodevelopmental Disorders with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: 1 Year to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Neurodevelopmental Disorders with a site in Spain, or all of them as a file.
02

Study summary

The aim of this randomized crossover clinical trial is to determine the effect of robot assisted gait training combined with physiotherapy on body composition and functional variables in a pediatric population with neurodevelopmental disorders.The main questions to answer are:

  • Does this treatment improve body composition parameters?
  • Does the treatment help maintaining functionality and without causing discomfort or pain?

Participants will perform 2 weekly physiotherapy sessions for 8 weeks, then there will be 4 weeks of washout, afer which each patient will cross over to the other group for 8 more weeks.

Read the detailed description

Pediatric population with neurodevelopmental disorders, such as cerebral palsy (CP), levels IV-V of the Gross Motor Function Classification System (GMFCS), do not walk independently due to their significant physical limitations, so their body composition may be altered, which in turn affects their functional level and may lead to the appearance of musculoskeletal complications. Robot assisted gait training (RAGT) offers a new opportunity to improve mobility of pediatric population with CP levels IV-V of GMFCS, although scientific literature is still scarce in this population.

The main aim of this study is to determine the effect of RAGT on body composition and functional variables in a pediatric population with neurodevelopmental disorders. Also to analyze changes in functional, musculoeskeletal, and stress biomarkers variables after the intervention, and to evaluate the cardiorespiratory adaptation to the RAGT.

A convenience sample of 10-12 participants will be selected, who will serve as their own control. It has been taken into account that previous studies conducted on pediatric population with CP this sample size is adequate.

At the beginning of the study, 50% of the participants will be part of the RAGT group, which will perform 2 weekly sessions of RAGT plus conventional therapy; and the other 50% will belong to the conventional physical therapy group. The study consists of phases 1 and 2 of treatment with a washout period between phases: after "phase 1" (8 weeks of therapy in one of the two groups), there will be 4 weeks of washout, after which each patient will cross over to the other group in "phase 2" (for 8 weeks).

Participants will be assessed before phase 1 (T1), after phase 1 (T2), before phase 2 (T3) and after phase 2 (T4).

03

Conditions studied

  • Neurodevelopmental Disorders
  • Cerebral Palsy

Keywords

  • cerebral palsy
  • neurodevelopmental disorders
  • robot assisted gait training
  • physical therapy
  • body composition
  • musculoeskeletal
04

Who can participate

Ages eligible
1 Year to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediactric population with neurodevelopmental disorders who have been diagnosed with cerebral palsy.
  • With a level IV or V of the GMFCS.
  • Adapted to the school environment (> 6 months).
  • Unable to stand without support.
  • Receiving conventional physiotherapy (> 6 months).
  • Receiving a standing program (standing duration at school: at least 45 minutes/day).
  • With ankle orthosis.
  • Meeting the specific criteria of the exoskeleton manufacturer (ATLAS 2030 Marsibionics https://www.marsibionics.com/): Weight less than 35 kg, Hip width less than 35 cm, Distance from the center of rotation of the hip to that of the knee between 24 and 33 cm, distance from the center of rotation of the knee to that of the ankle between 23 and 32 cm, the ankle can reach close to 90º with or without an orthosis, shoe size less than 33, hip and knee flexion less than or equal to 20º (even after having previously warmed up).

Exclusion criteria

Exclusion Criteria:

  • Severe spinal deformity.
  • Severe hip dysplasia.
  • Knee and hip flexion greater than 20º.
  • Children treated surgically within the 1-year period prior to the evaluation date.
  • Skin inflammation and open skin lesions around the trunk or limbs.
  • Uncontrolled epilepsy: active epilepsy resistant to medication.
  • Pacemaker, defibrillator or osteosynthesis material carriers.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    robot assisted gait training plus conventional physical therapy

    Participants will complete 8 weeks of intervention of robot assisted gait training plus conventional physical therapy.

    Combination Product: Robot assisted gait training plus conventional physical therapy

  • Active comparator
    Conventional physical therapy

    Participants will complete 8 weeks of conventional therapy.

    Other: Conventional pjysical therapy

Interventions

  • Combination productRobot assisted gait training plus conventional physical therapy

    Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.

  • OtherConventional pjysical therapy

    Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.

06

What researchers measure

Primary outcomes

  1. Body composition, fat %

    Measured by bioimpedanciometry (BIA): fat (%).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  2. Body composition, fat in kg

    Measured by bioimpedanciometry (BIA): fat (kg)

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  3. Body composition, lean mass (kg)

    Measured by bioimpedanciometry (BIA): lean mass (kg), lean mass (%), total mass (%), dry lean weight (%), Body mass index, and resistance at 50 kHz measured in Ohms

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  4. Body composition, lean mass (%)

    Measured by bioimpedanciometry (BIA): lean mass (%).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  5. Body composition, dry lean weight

    Measured by bioimpedanciometry (BIA): dry lean weight (%).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  6. Bone mineral density.

    Measured by ultrasound densitometry.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

Secondary outcomes

  1. Functional and musculoeskeletal assessmement, clinical data.

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): clinical data.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  2. Functional and musculoeskeletal assessmement, musculoskeletal history.

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): musculoskeletal history (previous history of fractures, subluxation or hip dysplasia), technical aids that are currently needed, neurorehabilitation treatments that are currently received at the center.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  3. Functional and musculoeskeletal assessmement, disability assessment

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): disability assessment using the Pediatric Evaluation Disability Inventory (PEDI), range of motion of lower limb joints (it will be measured with a goniometer for hip, knee and ankle), spasticity in the muscles of the lower limbs (it will be measured with the modified Asworth Scale), and also the functional capacity using the Functional Mobility Scale (FMS).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  4. Functional and musculoeskeletal assessmement, range of motion

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): range of motion of lower limb joints (it will be measured with a goniometer for hip, knee and ankle), spasticity in the muscles of the lower limbs (it will be measured with the modified Asworth Scale), and also the functional capacity using the Functional Mobility Scale (FMS).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  5. Functional and musculoeskeletal assessmement, spasticity

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): spasticity in the muscles of the lower limbs (it will be measured with the modified Asworth Scale), and also the functional capacity using the Functional Mobility Scale (FMS).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  6. Functional and musculoeskeletal assessmement, functional capacity

    Measured by the "Cerebral Palsy Follow-Up Program" (CPUP): functional capacity using the Functional Mobility Scale (FMS).

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  7. Anthropometric measurements, weight

    Weight (kg)

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  8. Anthropometric measurements, height

    Height (cm)

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  9. Anthropometric measurements, BMI

    Body Mass Index (kg/m2)

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  10. Anthropometric measurements, circumferences

    circumferences of arm, calf, waist and hip (cm)

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  11. Nutritional status

    The nutritional status of each participant will be defined by weight-for-age percentiles, height-for-age percentiles, weight-for-height ratio, and BMI-for-age, following WHO growth charts and ASPEN standards, as in previous studies in this population.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  12. Postural ability

    Posture and Postural Ability Scale (PPAS) in sitting, supine and prone.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  13. Cardio-respiratory measurement, heart rate

    Heart rate (HR) will be measured by pulse oximetry.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

  14. Cardio-respiratory measurement, oxygen saturation

    Oxygen saturation (SaO2) will be measured by pulse oximetry.

    Time frame: Before phase 1 (T1, pre intervention), after phase 1 (T2, after 8 weeks intervention), before phase 2 (T3, pre intervention) and after phase 2 (T4, after 8 weeks intervention).

Other outcomes

  1. Parameters of the RAGT intervention, total time

    During the RAGT intervention sessions, the following will also be recorded: Total session time (in minutes).

    Time frame: During RAGT intervention sessions (8 weeks).

  2. Parameters of the RAGT intervention, distance.

    During the RAGT intervention sessions, the following will also be recorded: number of steps and distance walked (in metres), walking speed (the two-minute walk test will be used), spasticity of the lower limbs before and after walking with the robot (modified Asworth scale), range of motion of the lower limb joints, recording of cardiorespiratory variables during walking with an exoskeleton (HR pre and post session, SaO2 pre and post session), respiratory rate and the Physiological Cost Index will be calculated ((Working HR - Resting HR) / Walking speed).

    Time frame: During RAGT intervention sessions (8 weeks).

  3. Parameters of the RAGT intervention, walking speed

    During the RAGT intervention sessions, the following will also be recorded: walking speed (the two-minute walk test will be used), spasticity of the lower limbs before and after walking with the robot (modified Asworth scale), range of motion of the lower limb joints, recording of cardiorespiratory variables during walking with an exoskeleton (HR pre and post session, SaO2 pre and post session), respiratory rate and the Physiological Cost Index will be calculated ((Working HR - Resting HR) / Walking speed).

    Time frame: During RAGT intervention sessions (8 weeks).

  4. Parameters of the RAGT intervention, spasticity

    During the RAGT intervention sessions, the following will also be recorded: spasticity of the lower limbs before and after walking with the robot (modified Asworth scale).

    Time frame: During RAGT intervention sessions (8 weeks).

  5. Parameters of the RAGT intervention, range of motion

    During the RAGT intervention sessions, the following will also be recorded: range of motion of the lower limb joints.

    Time frame: During RAGT intervention sessions (8 weeks).

  6. Parameters of the RAGT intervention, heart rate

    During the RAGT intervention sessions, the following will also be recorded: cardiorespiratory variables during walking with an exoskeleton, heart rate (HR) pre and post session.

    Time frame: During RAGT intervention sessions (8 weeks).

  7. Parameters of the RAGT intervention, SaO2

    During the RAGT intervention sessions, the following will also be recorded: SaO2 pre and post session

    Time frame: During RAGT intervention sessions (8 weeks).

  8. Parameters of the RAGT intervention, respiratory rate

    During the RAGT intervention sessions, the following will also be recorded: respiratory rate (cycles/minute)

    Time frame: During RAGT intervention sessions (8 weeks).

  9. Parameters of the RAGT intervention, Physiological Cost Index

    During the RAGT intervention sessions, the following will also be recorded: Physiological Cost Index will be calculated ((Working HR - Resting HR) / Walking speed).

    Time frame: During RAGT intervention sessions (8 weeks).

  10. Pain or discomfort

    Objectively measured by means of a saliva sample, analyzing the levels of salivary alpha-amylase (α-amylase) activity and salivary cortisol concentration. The first sample represents the child's initial stress level before the intervention program, and the second sample represents the child's stress response to the intervention. The first 5 days of conventional treatment are repeated at the same time. (Zhao, 2015) The saliva samples will be obtained using a Salivette device and processed in the favilities of IVIRMA Global Research Alliance, IVI Foundation -La Fe Health Research Institute.

    Time frame: Before and after the first 5 days of treatment (week 1 of each phase)

07

Study locations

1 site
  • University of Valencia
    Valencia, València 46010, Spain
08

References and documents

Publications

  • Engsberg JR, Ross SA, Collins DR. Increasing ankle strength to improve gait and function in children with cerebral palsy: a pilot study. Pediatr Phys Ther. 2006 Winter;18(4):266-75. doi: 10.1097/01.pep.0000233023.33383.2b. PubMed 17108800 ↗
  • McCormick AM, Alazem H, Zaidi S, Barrowman NJ, Ward LM, McMillan HJ, Longmuir P, Larin M, Dalton K. A randomized, cross-over trial comparing the effect of innovative robotic gait training and functional clinical therapy in children with cerebral palsy; a protocol to test feasibility. Contemp Clin Trials. 2023 Apr;127:107086. doi: 10.1016/j.cct.2023.107086. Epub 2023 Jan 17. PubMed 36669727 ↗
  • Peungsuwan P, Parasin P, Siritaratiwat W, Prasertnu J, Yamauchi J. Effects of Combined Exercise Training on Functional Performance in Children With Cerebral Palsy: A Randomized-Controlled Study. Pediatr Phys Ther. 2017 Jan;29(1):39-46. doi: 10.1097/PEP.0000000000000338. PubMed 27984466 ↗
  • Zhao X, Chen M, Du S, Li H, Li X. Evaluation of stress and pain in young children with cerebral palsy during early developmental intervention programs: a descriptive study. Am J Phys Med Rehabil. 2015 Mar;94(3):169-75; quiz 176-9. doi: 10.1097/PHM.0000000000000252. PubMed 25500686 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jun 2026, 20 months.

Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 20 months is below that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jun 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 17, 2024
StartActual
Oct 17, 2024
Primary completionActual
Jun 30, 2026was Oct 2026
CompletionActual
Oct 15, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
Oct 2026→Jun 30, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Jun 30, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06645795
Collaborators
Instituto de Investigacion Sanitaria La Fe, CEE Cruz Roja Valencia
Responsible party
Anna Arnal Gómez (Assistant Professor of Physiotherapy, University of Valencia) — Principal investigator
First posted
Oct 17, 2024
Start date
Oct 17, 2024
Primary completion
Jun 30, 2026
Completion
Oct 15, 2026
Last update
Oct 16, 2026

Study contacts

ANNA ARNAL-GOMEZ, Dr.
principal investigator · University of Valencia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion